DIVI S LABORATORIES LTD vs Elder Pharmaceuticals Ltd

A side-by-side comparison of DIVI S LABORATORIES LTD (DIVISLAB) and Elder Pharmaceuticals Ltd (ELDERPHARM) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, DIVI S LABORATORIES LTD leads DIVISLAB vs ELDERPHARM on 10 of 14 metrics (2 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation22
  • Profitability40
  • Growth10
  • Size & financial health30

Valuation

Even

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

95.04
P/E ratio
0.00
10.62
P/B ratio
0.00
0.33%
Dividend yield
0.00%
₹96.73
EPS
₹-3.18

Profitability

DIVISLAB takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

16.50%
Return on equity
-45.60%
22.00%
Return on capital
-4.00%
33.00%
EBITDA margin
-44.00%
24.32%
Net margin
-0.70%

Growth

DIVISLAB takes 1/2

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

10.78%
Revenue CAGR (3Y)
1.27%
12.10%
Profit CAGR (3Y) even

Size & financial health

DIVISLAB takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹2.43L Cr
Market cap
₹0 Cr
₹10,560 Cr
Revenue
₹997 Cr
₹2,568 Cr
Net profit
₹-7 Cr
0.00
Debt / equity even
0.00
DIVI S LABORATORIES LTD
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 39.0%"]
  • ["Stock is trading at 14.6 times its book value", "The company has delivered a poor sales growth of 8.67% over past five years."]
Elder Pharmaceuticals Ltd
  • + ["Company has reduced debt.", "Stock is trading at 0.11 times its book value", "Debtor days have improved from 81.3 to 60.7 days."]
  • ["Company has low interest coverage ratio.", "The company has delivered a poor sales growth of 9.95% over past five years.", "Company has a low return on equity of -9.04% over last 3 years.", "Contingent liabilities of Rs.161 Cr.", "Company's cost of borrowing seems high"]
DIVI S LABORATORIES LTD full analysis Elder Pharmaceuticals Ltd full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.

DIVISLAB vs ELDERPHARM: Share Price, Valuation & Which to Buy | DocStoX